Mark W. Hahn
Overview
Mark W. Hahn received an average of $3M in total compensation, including $416K in salary, at Verona Pharma plc between 2021 and 2022. Mark Hahn also received $5M at Dova Pharmaceuticals in 2018.
Source: SEC filings on March 21, 2023 and March 15, 2019.
Related executives
We found nine more executives who work or worked at Verona Pharma plc and Dova Pharmaceuticals.
David Zaccardelli
Verona Pharma plc
Chief Executive Officer
Kathleen Rickard
Verona Pharma plc
Chief Medical Officer
Mark Hahn
Verona Pharma plc
Chief Financial Officer
Jan-Anders Karlsson
Verona Pharma plc
Chief Executive Officer
David Zaccardelli
Dova Pharmaceuticals
Chief Executive Officer
Kevin Laliberte
Dova Pharmaceuticals
Senior Vice President, Product Development
Alex Sapir
Dova Pharmaceuticals
Chief Executive Officer
Lee Allen
Dova Pharmaceuticals